Redeye considers Arise’s Q3 report to be very solid and almost completely in line with our estimates...
Redeye see a Q3 report from Genovis that came in just above our estimates in terms of sales but deli...
Redeye updates on EG7 following its Q3-results which saw lower topline than expected while EBITDA wa...
Redeye updates on GiG following its Q3-results which came in somewhat lower than expected.
Redeye expects an eventful 2024 for Lifecare following the Q3 report, which sported slightly higher ...
Redeye comments on Thunderful Group’s Q3'23 report, showing weaker sales but stronger profitability ...
Redeye provides a preview ahead of Fragbite Groups Q3 2023 report while also discussing its latest a...
Small estimate changes after Q3 SEK 6.1/sh of net cash and good position for more growth P/NAV of 0.
Algo could potentially start to rebound in the coming quarters '23e-'25e sales down 9-15% '24e EV/EB...
Medicinteknikbolaget Tendo redovisade ingen nettoomsättning och ökad rörelseförlust i det tredje kva...
Equity analyst Markus Almerud discusses Zwipe after the announcement of the rights issue.
ChargePanel publicerade den 14 november år 2023 bolagets delårsrapport för det tredje kvartal 2023.
Rapportkommentar Q3 Corlines Q3-rapport levde inte upp till marknadens förväntningar.
Låg sportboksmarginal pressar tillväxt och lönsamhet Omsättningen i kvartalet uppgick till EUR 9,9m,...
Q3 EBITDA of -0.3m vs ABGSCe 0.9m Strong financial position - Holds SEK 6.
Back into black numbers, adj. EBITA SEK 10.8m (21.6m) Lower sales but higher EBIT for '24e Stable de...
Exel’s CMD added details to its new strategy. Many important decisions are still to be worked out, b...
Redeye judges Fluoguide’s phase IIb trial with FG001 in high-grade glioma meeting its primary endpoi...
Redeye comments on EG7’s Q3-results where topline came in below expectations while EBITDA was better...
Redeye makes positive estimate revisions on the back of Bredband2’s strong Q3 2023 report that beat ...
